• Bernstein analyst Lee Hambright has lowered the price target for Boston Scientific (NYSE:BSX) to $54.00 from $60.00.
• Boston Scientific shares are currently lagging the broader market and the Medical sector, with the stock closing at $42.60 on October 2, 2026.
• The medical device company is scheduled to report its earnings on October 28, with analysts anticipating earnings per share (EPS) of $0.76 and revenue of $5.23 billion.

Boston Scientific (NYSE:BSX) makes medical devices used in areas such as heart care and surgery. Bernstein analyst Lee Hambright lowers the stock’s price target to $54.00 from $60.00. A price target is an analyst’s estimate of where a stock may trade. From Boston Scientific’s $42.60 price at the time of publication, the new target implies about 26.80% upside.

The lower target comes as Boston Scientific shares lag the broader market. As highlighted by Zacks Investment Research, the stock closes at $42.60 on October 2, 2026, down 1.46% for the session while the S&P 500 gains 0.73%. Over the preceding month, Boston Scientific falls 7.92%, compared with a 3.74% decline in the Medical sector.

Hambright’s $54.00 target is also below the $70.19 average 12-month target from 31 research firms, as highlighted by Defense World. The group’s consensus rating for Boston Scientific stock is “Moderate Buy”: 23 analysts rate Boston Scientific a buy, six a hold and two a sell. Other targets include $56.00 from Robert W. Baird, $60.00 from Leerink Partners and $65.00 from Piper Sandler.

Boston Scientific is scheduled to report earnings on October 28. Analysts expect earnings of $0.76 per share, up 1.33% from a year earlier, and revenue of $5.23 billion, up 3.25%. Earnings per share (EPS) measures profit assigned to each share, while revenue is the money the company brings in from sales.